New drug Kylo-11 targets hidden heart risk in early human test
NCT ID NCT06363851
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-stage study tested a single dose of Kylo-11 in 71 healthy adults with high levels of Lp(a), a protein linked to heart disease. The main goal was to check safety and how the drug moves through the body. Researchers also looked at whether Kylo-11 could lower Lp(a) levels, which might help control heart disease risk in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chengdu Xinhua Hospital
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.